The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
News|Articles|July 14, 2015
3M Launches Production-Scale Sizes of its Upstream Purifiers
Author(s)Pharmaceutical Technology Editors
The new sizes follow the 2014 launch of the company’s fully disposable purifier.
Advertisement
3M announced the launch of production-scale variants of its year-old upstream product, the Emphaze AEX Hybrid. The new sizes can accommodate process volumes of up to 25,000 liters.
According to the company, use of the purifier can reduce host-cell protein load by 25–35% and helps increase Protein A column output purity while requiring less aggressive column cleaning, effectively extending the life of a chromatography column.
Source: 3M
Advertisement
Related to this article
Pauric Bannigan, Intrepid Labs, explains how physics-informed machine learning aids formulation and why regulators still want experimental data.
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
Pauric Bannigan, Intrepid Labs, explains where AI speeds formulation decisions, why data is the bottleneck, and how active learning trains models with far less data.
Stephanie Johnson, Pfizer, explains how off-platform triggers, single-owner risk registers, and traceable prior knowledge keep protein formulation programs on track.
Stephanie Johnson, Pfizer, discusses how platform formulations moved 2 Pfizer protein programs to IND in 8 months by redistributing, not removing risk.
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
Advertisement
Advertisement